Rapamycin + Acarbose

Verdict: Probable (in mice — among the largest combined effects in ITP history) Last reviewed: 2026-04-25

TL;DR

The Strong et al. 2022 ITP cohort tested rapamycin + acarbose in combination and produced +34% median lifespan in males, +28% in females — among the largest combined effects ever reported by the ITP. The combination is mechanistically coherent: acarbose blunts post-prandial glucose excursions (reducing mTOR signaling at the gut/hepatic level), rapamycin inhibits mTOR directly. Together they engage the pathway by independent routes. Human translation: zero direct trials; off-label longevity-medicine practice combines them based on mouse data.

Why this combination

Rapamycin engages mTOR directly. Acarbose engages mTOR indirectly via reduced post-prandial insulin/IGF-1 signaling and possibly via microbiome shifts. The two interventions might be expected to:

1. Compound — engaging different parts of the same pathway with possibly synergistic effect
2. Compensate — acarbose's male-biased effect may be partly addressed by rapamycin's broader sex coverage

The ITP data is consistent with both, with the combined female effect (+28%) reflecting rapamycin filling in where acarbose alone is weak.

Component verdicts

• Rapamycin alone: Probable (anchor) → see interventions/rapamycin.md
• Acarbose alone: Probable (mice) / Suggestive (humans) → see interventions/acarbose.md

Combination evidence

Mouse (T3 — strong, ITP)

Strong et al. 2022, Aging Cell — ITP cohort:

• Rapamycin + acarbose combination
• Median lifespan: males +34%, females +28%
• Vs rapamycin alone: combination is larger than rapamycin's standalone effect (~22% males, ~28% females in earlier cohorts)
• Vs acarbose alone: combination is much larger than acarbose alone, especially in females
• Late-life initiation effective

This is among the cleanest synergy demonstrations in ITP history.

Human (T0)

• No formal trial of the rapamycin + acarbose combination for aging endpoints.
• Off-label longevity-medicine practice in some clinics uses both; protocols are entirely empirical.
• Side effect profiles overlap minimally — rapamycin's GI effects (mouth sores, mild lipid changes) and acarbose's GI effects (gas, bloating) operate via different mechanisms.

Safety considerations

• Rapamycin's known concerns (immune modulation, glucose handling — paradoxically can raise glucose despite the longevity story) interact non-trivially with acarbose's glucose-lowering effects. Net direction in healthy adults at low doses unclear.
• Both drugs have decades of clinical use in their indicated populations; combined use is not novel pharmacologically (some patients legitimately take both for medical indications).

Translation status

The most-actionable inference from this combination's evidence:

• For longevity-medicine clinicians prescribing rapamycin off-label, adding low-dose acarbose may amplify benefit based on mouse data. Evidence base is mouse-only; methodology says this is at most Suggestive for humans.
• For longevity-curious readers without a clinician relationship: this is not actionable without medical supervision; both drugs require monitoring.

Calibrated verdict

Probable in mice; Suggestive in humans (extrapolation only). The mouse evidence is among the strongest combined-intervention data in aging research. Human translation is essentially absent.

Open questions

• Q: Is anyone running or planning a rapamycin + acarbose human trial for aging endpoints?
• Q: Does the combination's superiority over rapamycin alone hold in animal models other than UM-HET3?
• Q: For humans on rapamycin for longevity, does adding low-dose acarbose meaningfully alter the metabolic side effect profile of rapamycin (glucose, lipids)?

Sources

• Strong et al. 2022 — ITP rapamycin + acarbose combination
• See also interventions/rapamycin.md and interventions/acarbose.md

Produced under methodology locked 2026-04-24.